ADC CDMOs — Bioconjugation, HPAPI & GMP Rankings · 2026
· updated as new inspection, certificate, and trial data enters the platform
9
CDMOs tracked
9
Fully scored
6
With FDA records
30
FDA inspections
96
EMA/MHRA GMP certs
2
Warning letters
Antibody-drug conjugates pair a targeting antibody with a cytotoxic payload via a chemical linker — a three-component process that crosses biologics, small-molecule, and HPAPI (high-potency API) disciplines. Manufacturing demands purpose-built containment (typically OEB-5), wet-chemistry linker-payload synthesis, and validated bioconjugation under GMP.
Selecting an ADC CDMO turns on commercial bioconjugation track record, containment level, the linker / payload chemistries already in their book of business (vc, mc, glucuronide; MMAE, MMAF, DM1, DM4, Dxd, calicheamicin, PBDs, etc.), drug-substance + drug-product capability, and clean FDA + EMA/MHRA inspections. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 10 NAI (no action), 18 VAI (voluntary action), 2 OAI (official action). Leading inspection & GMP sites: United States (24), UNITED KINGDOM (21), Denmark (18), Germany (13), UNITED STATES (8).
Last updated 2026-10-06. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
AG
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
|
78.6 | 100.0 | 2 insp · 23 GMP | Available | 2 programs |
| 2 |
Lonza
Basel, Switzerland
|
76.0 | 95.7 | 2 insp · 8 GMP | — | 1 programs |
| 3 |
CR
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
|
90.9 | 98.3 | 8 insp · 11 GMP | Limited | 0 programs |
| 4 |
PR
Piramal Pharma Solutions
Lexington, KY · Riverview, MI · Ahmedabad, IN
|
83.3 | 95.0 | 5 insp · 13 GMP | — | 0 programs |
| 5 |
WB2
WuXi Biologics
Shanghai, CN · Wuxi, CN
|
82.9 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 6 |
SK
SK pharmteco
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
|
79.5 | 100.0 | — | Available | 0 programs |
| 7 |
Catalent
Bagsværd, Denmark (operating under Novo Holdings)
|
73.1 | 74.9 | 12 insp · 37 GMP | — | 0 programs |
| 8 |
CA
Catalent (Novo Holdings)
Harmans, MD · Gosselies, BE
|
73.1 | 74.9 | 1 insp · 0 GMP | Available | 0 programs |
| 9 |
SB
Samsung Biologics
Incheon, South Korea, Rockville, Maryland, USA
|
61.5 | — | — | Available | 0 programs |
What to evaluate in a ADC (Antibody-Drug Conjugate) CDMO
HPAPI containment
Look for OEB-5 (sub-microgram occupational exposure band) suites for handling cytotoxic payloads end-to-end. Containment maturity is the floor for credible commercial ADC work.
Linker-payload chemistry on file
Match the CDMO's payload + linker experience to your program. MMAE / vc-MMAE is the most common; PBDs, calicheamicin, Dxd-class topoI inhibitors, and TLR agonists each carry distinct handling and analytical demands.
Commercial bioconjugation track record
Has the CDMO conjugated a commercially-approved ADC? Track record on Polivy, Padcev, Trodelvy, Enhertu, Tivdak, Elahere, Adcetris, Mylotarg, Besponsa, Lumoxiti, Blenrep, etc. is a strong qualifying signal.
Integrated DS + DP
Bioconjugation produces ADC drug substance; you'll also need sterile fill-finish for drug product. Confirm whether the CDMO covers both or partners — both routes work, but integrated is faster on transfer.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
Integrated ADC CDMOs vs multi-site coordination
ADC manufacturing has four distinct steps: monoclonal antibody production, payload synthesis, linker chemistry, and bioconjugation. Full-service ADC CDMOs — a small set including Lonza, WuXi Biologics, and Piramal Pharma Solutions — handle all four in-house. Most CDMOs specialize in one or two steps and coordinate with sponsors for the rest. Fully integrated is faster and simplifies comparability, but often comes with less flexibility on payload chemistry. Sponsors should map which steps each CDMO handles internally vs externally and price the coordination overhead accordingly — a two-CDMO ADC program typically adds 3–6 months of transfer and comparability work.
HPAPI containment for ADC payloads — what to ask
ADC payloads (tubulin inhibitors like MMAE and DM1, topoisomerase inhibitors like Dxd, DNA-damaging agents like PBDs and calicheamicin) are Category 3–5 high-potency compounds requiring specialized containment. CDMOs vary widely on containment maturity: dedicated HPAPI suites, negative-pressure isolators, single-use containment technology, and validated occupational exposure limits (OEL) below 1 µg/m³ (OEB-5). The FDA inspection record shown in the ranked table above reflects containment discipline under regulator scrutiny. Sponsors should also verify the CDMO's HPAPI-specific incident history and whether payload production is co-located with conjugation or shipped between sites.
Conjugation platform — random vs site-specific
Random cysteine or lysine conjugation is the mature ADC platform used by Kadcyla, Adcetris, Enhertu, Trodelvy and other approved ADCs; most CDMOs support it. Site-specific conjugation (engineered cysteines like ThioMab, unnatural amino acids, glycan-based like GlyCLICK) is the emerging platform for cleaner drug-antibody ratio (DAR) control and homogeneity. CDMOs differ in which conjugation platforms they've validated at GMP scale. Sponsors should confirm not just the CDMO's conjugation menu but demonstrated DAR consistency at intended commercial scale and the CDMO's process for handling homogeneity outliers.
How CDMO Signal computes the ADC ranking
The ADC Signal Score is the platform's standard four-pillar composite. Quality Compliance (35%) leans on FDA inspection classifications, Warning Letter history, and EMA/MHRA GMP certificate density — this pillar carries particular weight for ADC because HPAPI containment is inspection-verified and regulatory posture on ADC is still evolving. Operations (25%) reflects ClinicalTrials.gov sponsor and program footprint. Financial Stability (20%) draws on SEC filings and parent-company signals — ADC is capital-intensive with specialized facilities, so parent-company health matters for long-cycle commercial engagements. Capacity Intelligence (20%) tracks monitored trade press for facility expansions and ADC-specific capacity announcements. Full weightings at cdmosignal.com/methodology.
ADC (Antibody-Drug Conjugate) CDMOs — Frequently Asked Questions
Who are the top ADC (Antibody-Drug Conjugate) CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked ADC (Antibody-Drug Conjugate) CDMOs include AGC Biologics, Lonza, Charles River Laboratories. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many ADC (Antibody-Drug Conjugate) CDMOs have FDA inspection records?
CDMO Signal tracks 6 ADC (Antibody-Drug Conjugate) CDMOs with FDA inspection records and 96 EMA/MHRA GMP certificates across the group.
What's the difference between an ADC CDMO and a biologics CDMO?
A biologics CDMO makes the naked antibody (drug substance). An ADC CDMO additionally handles the cytotoxic payload synthesis and the bioconjugation step under HPAPI containment. Some large CDMOs (Lonza, Catalent) do both; others specialize in conjugation only and source the antibody from a biologics partner.
Which CDMOs have made commercially-approved ADCs?
Several CDMOs have commercial ADC track records. The rankings above show our scored ADC players — Lonza (Polivy, Padcev), Catalent (multi-program commercial conjugation), Piramal, AGC Biologics, Samsung Biologics, WuXi Biologics, Charles River — with FDA inspection and GMP detail per profile.
What HPAPI containment level should an ADC CDMO have?
OEB-5 (sub-microgram per cubic meter occupational exposure band) is the standard floor for handling MMAE, MMAF, DM1, DM4, Dxd, PBDs, and calicheamicin-class payloads. Some legacy payloads can run in OEB-4 but commercial work is OEB-5.
Related modalities